Home Fashion ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance...

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Medical Program of First-in-human Gamma-delta T Cell Activating Antibody and Speed up Growth of Disruptive Immunotherapeutic Pipeline

  • Vital spherical will allow the Firm to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Part II trials
  • Collection C provides world buyers Earlybird, Andera Companions, Invus and affected person group The Leukemia & Lymphoma Society Remedy Acceleration Program® to the syndicate

Marseille, France, June 13, 2022ImCheck Therapeutics introduced in the present day the shut of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Companions. The Collection C spherical (EUR 80 Million – USD 86 Million) and the final excellent tranche of Collection B transformed in Collection C shares (EUR 16 Million – USD 17.2 Million) solidifies ImCheck’s monetary place and management within the gamma-delta T cell house. Invus and The Leukemia & Lymphoma Society Remedy Acceleration Program® additionally joined the spherical as new buyers. Present buyers together with the Progress Alternative Fund of founding investor Kurma Companions, Eurazeo, Gimv, EQT Life Sciences (beforehand LSP), Boehringer Ingelheim Enterprise Fund, Pfizer Ventures, Bpifrance by means of its Innobio 2 and Massive Enterprise funds, Wellington Companions, Agent Capital, Pureos Bioventures and Alexandria Enterprise Investments participated.

The proceeds shall be used to help the Part IIa growth arms of EVICTION in stable tumors and hematologic cancers, and completion of randomized, double-blind, placebo-controlled scientific trials evaluating ImCheck’s lead candidate ICT01 together with a PD-1 inhibitor for a number of stable tumors. The Firm additionally will apply the capital to research ICT01 together with different therapeutic brokers, together with IL-2, within the forthcoming EVICTION-2 scientific trial. The funding will speed up the additional advance towards the clinic of further antibody candidates in immuno-oncology, auto-immune and infectious ailments. As well as, it can enable the Firm to attain pivotal examine readiness for ICT01 and develop its footprint by means of prolonged scientific operations and regulatory affairs in Europe and the US.

Since its inception, ImCheck has gained the help of a syndicate of excellent worldwide funds. In a extremely difficult funding market, we have secured a major fundraising by means of the addition of extremely strategic and precious buyers from the U.S. and Europe, placing us ready to additional ship on the immense promise of our pipeline,” said Pierre d’Epenoux, Chief Govt Officer of ImCheck Therapeutics. We view our singular proprietary place with butyrophilins, which provide highly effective immunomodulation of each the innate and adaptive immune methods, as the important thing to therapeutic intervention for a lot of illness indications and we worth the help we’re now gaining from The Leukemia & Lymphoma Society Remedy Acceleration Program® as a primary funding from a most cancers affected person nonprofit group.

At the side of the financing spherical, Florent Gros (Earlybird) and Raphaël Wisniewski (Andera Companions) will be a part of the Firm’s Board of Administrators.

Florent Gros, Associate at Earlybird, commented, ImCheck’s strategy to immuno-oncology is very differentiated by means of the scientific demonstration of gamma-delta T cell activation, an space of immunology that has big potential and curiosity from the biopharmaceutical neighborhood. At Earlybird, we help firms that dare to assume in another way and ImCheck’s revolutionary idea for immunomodulation could possibly be a game-changer for a spread of indications.”

Raphaël Wisniewski, Associate at Andera Companions, stated, Immune checkpoint inhibitors have heralded a brand new period in most cancers therapies and ImCheck Therapeutics is pioneering the subsequent technology of those immunotherapeutics. In watching their progress up to now, we have now seen the management crew execute on a compelling imaginative and prescient for a butyrophilin-based therapeutic strategy from the early growth stage right into a extremely precious scientific growth program. We at Andera Companions are assured the corporate will transfer its groundbreaking know-how ahead to fulfill sufferers’ wants in a spread of most cancers indications with wider potential for auto-immune and infectious ailments.”

ImCheck Therapeutics’ immunotherapeutic know-how is able to overcoming the tumor’s resistance to adaptive immune responses by means of a novel superfamily of immune checkpoint targets, butyrophilins (BTNs). BTNs could be modulated to harness a variety of immune cells together with gamma-delta T cells, CD3, CD8, NK cells and macrophages, bridging the innate and adaptive immune responses. The corporate’s broad pipeline is constructed upon immunomodulation through BTN-targeting antibodies aimed both at activating the immune system in illness indications akin to most cancers or infectious ailments, or down-regulating immunity in auto-immune problems.

Hans Henrik Christensen, Chief Monetary Officer of ImCheck Therapeutics, added, “ImCheck has raised a complete of EUR 154 million since inception. We really admire the help from current and new buyers, which extends our money runway till 2026. This allows us to additional discover the pipeline in a product alternative we have now with our lead scientific candidate, ICT01.”

Authorized counsel for the Collection C transaction offered by Dentons Europe and McDermott Will & Emery. Investor relations help offered by Trophic Communications. French media and communications help offered by ATCG Companions.


ImCheck Therapeutics is designing and creating a brand new technology of immunotherapeutic antibodies concentrating on butyrophilins, a novel super-family of immunomodulators.

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of motion to concurrently modulate innate and adaptive immunity, ImCheck’s “first-in-class” activating antibodies might be able to produce superior scientific outcomes as in comparison with the first-generation of immune checkpoint inhibitors and, when utilized in mixture, to beat resistance to this group of brokers. As well as, ImCheck’s antagonist antibodies are being evaluated as potential therapies for a spread of autoimmune ailments.

Co-founder of the Marseille Immunopole cluster, ImCheck advantages from help from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide chief in γδ T cells and butyrophilins analysis; from the expertise of an skilled administration crew; and from the dedication of main US and European buyers.

For additional info: http://www.imchecktherapeutics.com and @ImCheckThx

Earlybird is a enterprise capital investor centered on European know-how firms. Based in 1997, Earlybird invests in all progress and growth phases of an organization and helps its portfolio firms with monetary sources, strategic help, in addition to entry to a global community and capital markets. Earlybird invests out of a household of centered and independently-managed funds: Digital West (Western Europe), Digital East (Rising Europe), Healthcare, UNI-X (College spinoffs), and Progress Alternative. With EUR 2 billion below administration throughout all fund streams, 8 IPOs, and 30 commerce gross sales, Earlybird is one among Europe’s most established and lively enterprise capital companies.

For additional info: www.earlybird.com, Twitter: http://www.twitter.com/EarlybirdVC LinkedIn: www.linkedin.com/firm/earlybird-venture-capital Fb: www.fb.com/EarlybirdVC

Created over 20 years in the past, Andera Companions is a significant participant in personal firm investments in France and internationally. Its groups handle over €3.5 billion in investments in life sciences (Andera Life Sciences), progress and buyout capital (Andera MidCap, Andera Growth, Andera Croissance, Andera Co-Make investments), sponsor-less transactions (Andera Acto) and ecological transition (Andera Infra).

Based mostly in Paris, with places of work in Antwerp and Munich, Andera Companions is wholly owned by its groups, which rely almost 90 professionals, of which 56 are funding professionals. It’s structured as a partnership and managed by a board of 10 companions. Accountable and dedicated, the administration firm usually types partnerships with non-profit sector entities and takes concrete motion within the combat towards world warming. Andera Companions has been licensed carbon impartial since 2018.

Andera’s 15-person life sciences crew brings collectively intensive expertise within the life sciences trade, personal fairness and enterprise capital. Lively since 2000, the crew has raised over €1.1 billion by means of its BioDiscovery household of funds and is at the moment investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in additional than 75 European and U.S. biotech and medtech firms.

For additional info, please go to www.anderapartners.com.

Press contacts

US and EU
Trophic Communications
Gretchen Schweitzer
+49 (0) 172 861 8540

Céline Voisin
+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39


The content material is by GlobeNewswire. DKODING Media isn’t accountable for the content material offered or any hyperlinks associated to this content material. DKODING Media isn’t accountable for the correctness, topicality or the standard of the content material.

Supply hyperlink


Is Blue Garlic Protected to Eat?

With a couple of noticeable exceptions, corresponding to blueberries, blue raspberry sweet, and sure cocktails, blue will not be a coloration you need...

Cease Checking Your 401k So A lot

Photograph: Shutterstock (Shutterstock)Now greater than ever, heed this recommendation: Cease your 401k so rattling...

State Division Officers Meet With Griner’s WNBA Group

The State Division confirmed the assembly, which concerned officers from its specialised workplace that advocates for hostages and wrongfully detained Individuals, however supplied...


Please enter your comment!
Please enter your name here

Most Popular

Too huge to jail: The story of HSBC and the Mexican drug cartel

In 2012, HSBC was fined $1.9bn and entered right into a Deferred Prosecution Settlement for facilitating the laundering of cash by the Mexican medication...

American Airways regional carriers hike pilot pay as scarcity persists

American Airways Embraer ERJ-145 regional jet plane as seen on closing strategy touchdown at New York JFK worldwide airport in NY, on February...

Recent Comments